Data contain potentially identifying information and the Ethics Committee of Toho University Ohashi Medical Center has imposed restrictions on making the data publicly available. Requests for data may be sent to the e-mail address of the managing office of the Ethics Committee at <ohashi.rinri@ext.toho-u.ac.jp>.

Introduction {#sec005}
============

Epidemiologic data suggest that the incidence and prevalence of nontuberculous mycobacterium (NTM) infections are increasing in many countries\[[@pone.0237071.ref001]--[@pone.0237071.ref006]\]. *Mycobacterium avium* complex (MAC), including *M*. *avium* and *M*. *intracellulare*, is the most common etiology of NTM\[[@pone.0237071.ref007],[@pone.0237071.ref008]\]. Although the progressive improvements in diagnostic technology such as chest computed tomography (CT) and genetic sequencing suggest that host and microorganism factors\[[@pone.0237071.ref009]--[@pone.0237071.ref012]\], as well as environmental factors\[[@pone.0237071.ref012]\], might be involved, the exact reason for the increasing prevalence of MAC remains unknown.

The clinical outcomes of pulmonary MAC disease vary widely. Some patients respond well to standard treatment including clarithromycin, ethambutol, and rifampicin, whereas others show resistance to standard treatment with poor outcomes, and some other patients remain stable without any treatment\[[@pone.0237071.ref007],[@pone.0237071.ref013]\]. Thus, it is critical to determine the predictors for the prognosis of patients with pulmonary MAC disease.

It has long been considered that the causative species are critical predictors, but the difference in the prognosis between *M*. *avium* and *M*. *intracellulare* infections remains uncertain\[[@pone.0237071.ref014],[@pone.0237071.ref015]\]. Other factors that are currently considered to aggravate pulmonary MAC disease are the presence of fibrocavitary type on radiography, a positive acid-fast bacilli (AFB) smear of sputum samples, and a larger affected area\[[@pone.0237071.ref007],[@pone.0237071.ref014],[@pone.0237071.ref016]--[@pone.0237071.ref018]\]. However, there have been few studies of the factors that exacerbate pulmonary MAC disease without treatment, and they were generally judged based on the initiation of treatment as an indicator of aggravation. Thus, the aim of the present study was to clarify the significant predictors of radiological aggravations of pulmonary MAC disease using only the data of treatment-naïve patients.

Methods {#sec006}
=======

Study population {#sec007}
----------------

From April 2011 to December 2018 at our institute, of the patients with suspected NTM, 568 NTM cases were newly identified by cultures. Of them, 295 were diagnosed with NTM disease according to the 2007 American Thoracic Society/Infectious Disease Society guideline\[[@pone.0237071.ref007]\]. Those with a past history of NTM disease and NTM other than MAC were excluded from the present study. Finally, 238 subjects were enrolled in the present study ([Fig 1](#pone.0237071.g001){ref-type="fig"}). The clinical findings of the subjects, including age, sex, past history of tuberculosis, laboratory data, and radiological findings, were obtained from their medical records and retrospectively evaluated. To identify the significant predictors and to exclude treatment bias, analysis of only 167 treatment-naïve subjects (patients who did not receive medications for MAC during the observation period, and their radiographic findings were evaluated at the time of diagnosis and 1 year later) was performed.

![Flow chart of patients diagnosed with pulmonary MAC disease between April 2011 and December 2018.\
MGIT = mycobacterial growth indicator tube, NTM = nontuberculous mycobacterium, MAC = *Mycobacterium avium* complex.](pone.0237071.g001){#pone.0237071.g001}

Ethics approval and consent to participate {#sec008}
------------------------------------------

This research was conducted using information previously collected in the course of normal care (without the intention to use it for research at the time of collection). The need for written, informed patient consent was waived in view of the retrospective and observational nature of the study. This study received ethical approval from the Special Committee of Toho University Ohashi Medical Center, which is an ethics committee that reviews research on human subjects (project registration number H20004).

Microbiological examination {#sec009}
---------------------------

AFB were cultured in a Mycobacteria Growth Indicator Tube (MGIT) from extracted sputum or bronchial washings obtained by bronchoscopy. The sputum samples were obtained on two or more occasions after the initial presentation. The diagnosis of MAC was confirmed when cultures were positive for AFB, and the cultured AFB was subsequently confirmed as MAC by PCR. The diagnosis of pulmonary MAC disease was established when MAC was identified in sputum at least twice or in bronchial washings\[[@pone.0237071.ref007]\].

Radiological examination {#sec010}
------------------------

According to a previous report\[[@pone.0237071.ref007]\], chest radiological findings were classified as fibrocavitary (FC) type or nodular/bronchiectatic (NB) type on high-resolution CT. Additionally, chest radiological findings at the time of initial diagnosis were scored as follows. The lung fields were divided into six zones based on anatomical structures, i.e. right upper, right middle, right lower, left upper, left lingular, and left lower. When any abnormal findings including cavities, bronchiectasis, small nodules, consolidations, atelectasis, and so on were found in a zone at the time of diagnosis, they were each counted as one point and summed up in the six zones (maximum 6 points). The subjects were further classified based on their radiological imaging findings during the follow-up period into three categories: exacerbation, no change, or improvement. Each category was defined as follows: exacerbation, abnormal shadows increased; no change, abnormal shadows remained stable on the whole; and improvement, abnormal shadows decreased. The three categories were classified by five respiratory specialists in a blinded fashion.

Patient management {#sec011}
------------------

When patients did not receive medications for MAC during the observation period, radiographic findings were evaluated at the time of the diagnosis and 1 year later. The patients who received medications for MAC during the observation period, not only those who began guideline-based therapy, but also those who discontinued medications, were excluded in the analysis of treatment-naïve subjects.

Statistical analysis {#sec012}
--------------------

The patients' characteristics are presented as medians (interquartile range). Numerical data are expressed as numbers (%). To identify factors related to pulmonary MAC disease in treatment-naïve patients, univariate and multivariate logistic regression analyses were used to estimate odds ratios (ORs) with 95% confidence intervals (CIs) for radiological aggravation. Additional analysis was added regarding the affected area that was significant as a factor aggravating pulmonary MAC disease. The sensitivity and specificity of the radiological aggravation prediction model were calculated for each score value. The performance of the radiological aggravation prediction model was evaluated using the receiver operating characteristic (ROC) curve by calculating the area under the ROC curve\[[@pone.0237071.ref019],[@pone.0237071.ref020]\]. All analyses were performed using SPSS Statistical software (version 22.0; IBM Japan, Tokyo, Japan). *P* values \< 0.05 were considered significant.

Results {#sec013}
=======

Baseline characteristics of pulmonary MAC patients {#sec014}
--------------------------------------------------

During the study period, 238 patients with pulmonary MAC disease were enrolled, and their baseline characteristics are summarized in [Table 1](#pone.0237071.t001){ref-type="table"}. The causative organisms included *M*. *avium* (189/238, 79.4%), *M*. *intracellulare* (36/238, 15.1%), and mixed infections (13/238, 5.5%). All patients were HIV-negative. Their median age was 76 (68--82) years, and 80% of patients were over 65 years of age. Female (68.1%), never-smoker (64.7%), and NB type (80.6%) were predominant in MAC patients. The median BMI was slightly low (19.0 kg/m^2^). Medications for MAC were given to 62 (26%) patients during the observation period. The median number of abnormal lung zones was 3.

10.1371/journal.pone.0237071.t001

###### Baseline characteristics of pulmonary MAC patients (n = 238).

![](pone.0237071.t001){#pone.0237071.t001g}

  ---------------------------------------------------------------- --------------------------
  Age (y)                                                          76 (68--82)
  Sex (male/female)                                                76 / 162
  Smoking history (current/past/never/unknown)                     2 / 72 / 154 / 10
  BMI (kg/m^2^)                                                    19.0 (16.8--21.5)
  TP (g/dL)                                                        7.4 (7.0--7.9)
  ALB (g/dL)                                                       3.8 (3.35--4.1)
  CRP (mg/dL)                                                      0.19 (0.04--0.99)
  Previous tuberculosis, n (%)                                     23 (9.7%)
  Lung disease other than mycobacterial disease, n (%)             96 (40.3%)
  Smear/culture/BALF                                               48 / 136 / 54
  Positive AFB smear, n (%)                                        48 (20.2%)
  *M*. *avium*/*M*. *intracellulare*/*M*. *avium+intracellulare*   189 / 36 / 13
  FC type/NB type                                                  46 (19.3%) / 192 (80.7%)
  MAC therapy during follow-up                                     62 (26.1%)
  Zone of radiological findings (n)                                3 (2--4)
  ---------------------------------------------------------------- --------------------------

Data are expressed as medians (interquartile range) or numbers (%).

AFB = acid-fast bacilli, ALB = serum albumin, BALF = bronchoalveolar lavage fluid, CRP = serum C-reactive protein, FC = fibrocavitary, MAC = *Mycobacterium avium* complex, NB = nodular/bronchiectatic, TP = serum total protein.

Predictors of exacerbation in treatment-naïve pulmonary MAC subjects {#sec015}
--------------------------------------------------------------------

To exclude the bias of treatment because the treatment period was not fixed, univariate analysis was performed using only the data of treatment-naïve subjects ([Table 2](#pone.0237071.t002){ref-type="table"}).

10.1371/journal.pone.0237071.t002

###### Predictors of radiological aggravation in treatment-naïve pulmonary MAC subjects (n = 167).

![](pone.0237071.t002){#pone.0237071.t002g}

                                                                     Univariate analysis    
  ----------------------------------------------- ------------------ ---------------------- ------------------------------------------------
  Age (y)                                         78(71--84)         0.985 (0.957--1.013)   0.297
  Sex (female)                                    109(65.3%)         1.728 (0.855--3.495)   0.128
  Never-smoker(%)                                 107(64.1%)         1.946 (0.935--4.050)   0.075
  BMI (kg/m^2^)                                   19.2(16.7--21.5)   0.916 (0.818--1.026)   0.129
  TP (g/dL)                                       7.3(6.8--7.9)      1.498 (0.937--2.396)   0.092
  ALB (g/dL)                                      3.6(3.3--4.1)      1.456 (0.839--2.529)   0.182
  CRP (mg/dL)                                     0.23(0.04--1.12)   0.925 (0.781--1.094)   0.363
  Previous tuberculosis, n (%)                    20(12.0%)          2.196 (0.855--5.639)   0.102
  No lung disease other than MAC disease, n (%)   80(47.9%)          2.903 (1.468--5.740)   0.002[\*](#t002fn002){ref-type="table-fn"}
  Positive AFB smear, n (%)                       32(19.2%)          3.020 (1.358--6.715)   0.007[\*](#t002fn002){ref-type="table-fn"}
  *M*. *intracellulare*(%)                        24(14.4%)          0.922 (0.371--2.288)   0.860
  FC type(%)                                      24(14.4%)          2.250 (0.938--5.400)   0.069
  Zone of radiological findings, n (%)            3(2--4)            1.979 (1.512--2.591)   \<0.001[\*\*](#t002fn003){ref-type="table-fn"}

See footnotes of [Table 1](#pone.0237071.t001){ref-type="table"} for expansions of abbreviations, OR = odds ratio

\*: *P*\<0.05

\*\*: *P*\<0.001

The univariate analysis showed that no lung diseases other than MAC, more extensive radiological findings, and positive AFB smear were significantly associated with radiological aggravations. Multivariate analysis was performed with factors that showed significant differences on univariate analysis (no lung diseases other than MAC, more extensive radiological findings, and positive AFB smear) ([Fig 2](#pone.0237071.g002){ref-type="fig"}). The radiological factor (larger affected area) and absence of other lung disease were significantly associated with radiological aggravations. Additional analysis, ROC curve analysis, was performed regarding the affected area that was significant as an aggravating factor of pulmonary MAC disease. In the zones of abnormal findings at the time of diagnosis, 7/74 (9.46%) of those with less than 2 zones affected had a radiological aggravation in one year, and 49/93 (52.7%) with more than 3 zones affected showed a radiological aggravation in one year ([Fig 3](#pone.0237071.g003){ref-type="fig"}). ROC curve analysis was performed to determine the threshold value when considering how many zones showing radiological findings was a risk. The ROC curve had an area under the curve of 0.765 for the radiological aggravation prediction model ([Fig 4](#pone.0237071.g004){ref-type="fig"}). A threshold of 3 was identified as the optimal number of zones from the ROC curve, with a sensitivity of 87.5% and a specificity of 60.4%.

![ORs and associated 95% CIs for radiological aggravation of pulmonary MAC disease.\
\* Significant independent factors for radiological aggravation of pulmonary MAC disease.](pone.0237071.g002){#pone.0237071.g002}

![Aggravation by number of lung lobes with abnormalities.\
The black bar shows the number with radiological aggravation in each number of abnormal lobes, and the white bar shows that it has not changed. X-axis: Number of abnormal lobes, Y-axis: Number of pulmonary MAC patients.](pone.0237071.g003){#pone.0237071.g003}

![The radiological aggravation prediction model: ROC curve.\
ROC: receiver operating characteristic. AUC: area under the curve, Cut-off value: 3, sensitivity 87.5%, specificity 60.4%.](pone.0237071.g004){#pone.0237071.g004}

Discussion {#sec016}
==========

In the present study, *M*. *avium* was the predominant species, found in 79.4% of MAC patients. The rate of patients with *M*. *avium* infection was similar to other recent reports\[[@pone.0237071.ref021]\]. Similarly, there were more female than male patients in the present study. Generally, pulmonary MAC diseases develop more frequently in female than in male patients. In Japan, more women than men often work around water, and wet environmental exposure might be involved\[[@pone.0237071.ref012]\]. A recent biological study reported the role of estrogen in the development of pulmonary MAC disease, whereas the role of sex in disease susceptibility has yet to be determined\[[@pone.0237071.ref022]\]. Generally, pulmonary MAC diseases develop more frequently in thin and never smoker patients\[[@pone.0237071.ref023]--[@pone.0237071.ref025]\]. In the present study, similarly, patients had slightly low BMIs, and approximately two-thirds of pulmonary MAC disease patients were never smokers.

The aim of the present study was to clarify the significant predictors of radiological aggravations of pulmonary MAC disease using only the data of treatment-naïve patients. To date, disease progression of pulmonary MAC disease was defined as either requiring the start of treatment\[[@pone.0237071.ref007],[@pone.0237071.ref014],[@pone.0237071.ref017]\] or the presence of aggravation on radiological imaging\[[@pone.0237071.ref026],[@pone.0237071.ref027]\]. In the present study, disease progression was defined as aggravation on radiological imaging. In some previous studies, the reason that the initiation of treatment was defined as an indicator of exacerbation was that MAC is indolent in nature, and thus, in many cases, radiological changes are difficult to evaluate on chest X-ray, detailed evaluation requires chest CT, and no radiological evaluation method for pulmonary MAC disease has been established globally. However, the timing of treatment may be biased by each doctor and each patient when using the initiation of treatment as evidence of exacerbation. For example, elderly patients tend to disagree with long-term medication, even if the doctor suspects deterioration and considers that they should be treated. Fortunately, in most of the present cases, CT was performed in our hospital, and it was possible to examine the changes in radiological evaluations.

In the present study, radiological aggravation over one year was found in 56/167 (33.5%) of treatment-naïve subjects. Previous studies reported that about 20--40% and 50% of pulmonary MAC patients showed radiological aggravations after 5 and 10 years, respectively\[[@pone.0237071.ref016],[@pone.0237071.ref026]\]. In the present study, the frequency of radiological aggravations was relatively high within only one year because of the absence of treatment. In the present study, the absence of other underlying lung diseases and the presence of more extensive radiological findings (larger affected area) in untreated patients were associated with radiological aggravations based on the probabilities of reactivation or dissemination of the infection. The present analysis indicated that the more extensive the radiological findings at initial diagnosis, the more likely a subsequent MAC aggravation becomes, which is in accordance with the findings of previous studies\[[@pone.0237071.ref017],[@pone.0237071.ref018]\]. Previous studies reported that, in addition to extensive radiological findings, positive sputum AFB smear\[[@pone.0237071.ref007],[@pone.0237071.ref017]\], FC type\[[@pone.0237071.ref007],[@pone.0237071.ref016]\], and lower BMI\[[@pone.0237071.ref016],[@pone.0237071.ref018]\] were aggravating factors. It is difficult to make a strict comparison between the current study and previous studies, because previous studies that treated patients are included, or they defined exacerbation as requiring treatment. In the present study, positive AFB smear, FC type, and lower BMI were not associated with radiological aggravations, but positive AFB smear (OR 3.020, 1.358--6.715) tended to be more common in patients with MAC disease aggravations.

No studies examined the presence or absence of underlying lung diseases as an aggravating factor in pulmonary MAC disease. The present study demonstrated that the absence of other underlying lung diseases in untreated MAC patients was a significant aggravating factor of pulmonary MAC disease. Patients having other underlying lung diseases seemed to undergo radiological examinations more frequently than those without other underlying lung diseases. Thus, there may be more opportunities to identify the early phase of pulmonary MAC disease in those with underlying lung diseases. However, it cannot be ruled out that the diseases themselves, such as some kind of lung disease, and part of their treatment may be factors that suppress the progression of pulmonary MAC disease\[[@pone.0237071.ref028]\]. These will be our future research targets. Additionally, more extensive radiological findings were found to be an aggravating factor in the present analysis; therefore, a simple radiological scale assessment was performed with additional analysis by ROC curve analysis. Although some authors reported radiological scoring methods in pulmonary MAC disease\[[@pone.0237071.ref029],[@pone.0237071.ref030]\], they were complicated and required much effort. Compared to these reports, the present scoring system had some limitations and merits. It simply counted the number of abnormal lesions, irrespective of their volume and characteristics. Nonetheless, it can be easily performed in actual clinical practice and can potentially predict the natural course of pulmonary MAC disease, as suggested by the present report. With abnormal lesions in more than 3 zones, approximately half of the cases showed aggravation on imaging within one year, but with lesions in less than 2 zones, less than 10% showed aggravation. An ROC curve to determine the threshold value when considering how many zones of radiological findings are a risk identified 3 as the ideal threshold. Thus, treatment might be considered within one year when MAC disease involves 3 or more zones at the initial diagnosis.

Limitations {#sec017}
===========

Some limitations of the present study should be addressed. This study was limited by its retrospective nature without randomization, and it was a single-institution study, and as such, it is not representative of the national population. Additionally, this was a short-term study, and the number of MAC patients may have been underestimated since patients who were not diagnosed according to the 2007 American Thoracic Society/Infectious Disease Society guideline were excluded from the analyses. Therefore, factors with clinical significance in reality may have proven insignificant in the analyses with reduced statistical power.

Conclusion {#sec018}
==========

Women and never-smokers were predominant among patients with pulmonary MAC diseases. The critical factor for radiological aggravation of pulmonary MAC disease over a 1-year period is the presence of extensive abnormal shadows, especially the presence of abnormal shadows in ≥3 lobes in the lung. Thus, clinical attention should be focused on early diagnosis, because the presence of more extensive radiological findings (larger affected area) in untreated patients was associated with radiological aggravation.

ALB

:   serum albumin

CRP

:   serum C-reactive protein

CT

:   computed tomography

FC

:   fibrocavitary

MAC

:   *Mycobacterium avium* complex

NB

:   nodular/bronchiectatic

NTM

:   : nontuberculous mycobacterium

TP

:   serum total protein
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We also asked a native English-speaking medical editor to check the paper.

Comment

Reviewer \#2:

This is a retrospective study looking into factors associated with the exacerbation of pulmonary MAC infection. The statistical analysis mainly focused on the association between sex and smokers, as shown in Tables 2, 3 and 4. However, these analyses are indeed redundant and could be simplified into one table in Table 5 that looks into the main theme of this study, which is to identify the factors associated with the exacerbation of pulmonary MAC disease. An assumption could be made that the authors do not know the statistical method and taking such a redundant way. Besides, the multivariate analysis is not clear of what the authors are looking for, and the criteria for selecting the variates seem to be not justified making the results unreliable. Not only the statistical analyses are

unreliable, but the results also are not new and tell the readers nothing additional to the clinical practice.

Response

We wish to thank the reviewer for the comments.

The number of patients with pulmonary MAC disease is increasing worldwide, especially among women and never-smokers. The roles of female hormones and adiponectin have been suggested, though the underlying mechanisms are yet to be determined. We did a simple analysis of this, and in the process, we found it was easier to detect MAC disease relatively early in smokers, due to the presence of other diseases. Therefore, we decided to perform additional analysis.

As you suggested, the presence of more extensive abnormal shadows has been previously shown to be associated with exacerbations of pulmonary MAC disease.

The new information provided by this study is that the most critical exacerbating factor of pulmonary MAC disease over 1 year is the presence of extensive abnormal shadows, especially the presence of abnormal shadows in ≥3 lobes in the lung. This information had never been reported by previous studies.

Our scoring system involves simply counting the number of abnormal lesions in the lung fields divided into six zones based on anatomical structures; thus, this system is far removed from previous detailed scoring systems, which are complicated and required much more effort. In contrast, our scoring system is simple and quick, so it can be easily performed in actual clinical practice. We therefore believe this paper merits publication.

Regarding statistics, some of the parameters showed high standard deviation. It would be more appropriate to give the interquartile range for all parameters to understand the significance better. Thus, we changed all parameters to include interquartile ranges.

###### 

Submitted filename: Response to Reviewers.docx

###### 

Click here for additional data file.
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© 2020 Selvakumar Subbian

2020

Selvakumar Subbian

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

5 Feb 2020

PONE-D-19-29751R1

Predictors of exacerbations of pulmonary MAC disease

PLOS ONE

Dear Dr. Matsuse,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR: A major issue in this manuscript that has not been satisfactorily addressed is the statistical analysis of the retrospective data. Therefore, it is important that the authors explicitly explain the statistical analysis and the tools used etc., in the methods or results section (refer reviewer comment).  Also, it is important to discuss the limitations of this study. Include a paragraph in the discussion section that describes all type of limitations applicable to this retrospective analysis.

We would appreciate receiving your revised manuscript by Mar 21 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Selvakumar Subbian, Ph.D.

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The manuscript titled "Predictors of exacerbation of pulmonary MAC disease" is written well and interesting to note the new scoring system for pulmonary involvement. The authors claim that "The new information provided by this study is that the most critical exacerbating factor of pulmonary MAC disease over 1 year is the presence of extensive abnormal shadows, especially the presence of abnormal shadows in ≥3 lobes in the lung. This information had never been reported by previous studies". There is a certain bias in the age group who are all elders above 69. It does not represent the age distribution within a normal population. Besides, there are no representative images to explain the scoring system. The data on the co relation to sex and smoking status does not add any value to the idea mentioned in the title. Also, only 39 people have received MAC therapy. Although this is a very notable finding by the authors, in my opinion, it does not warrant its publication as a full-length manuscript but a brief communication.

Reviewer \#2: I appreciate your response to my comments. Statistical methods are basically the same. As previously mentioned, there is nothing novel to our clinical practice. The author\'s comment indicates the presence of a scoring system, which is not mentioned in the manuscript.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Radha Gopalaswamy

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0237071.r004

Author response to Decision Letter 1

6 Mar 2020

PONE-D-19-29751

Predictors of exacerbations of pulmonary MAC disease

PLOS ONE

Academic Editor

We wish to thank the academic editor for the comments.

Comment

1\) A major issue in this manuscript that has not been satisfactorily addressed is the statistical analysis of the retrospective data. Therefore, it is important that the authors explicitly explain the statistical analysis and the tools used etc., in the methods or results section (refer reviewer comment). Also, it is important to discuss the limitations of this study. Include a paragraph in the discussion section that describes all type of limitations applicable to this retrospective analysis.

Response

As you suggested, our statistical analysis of the retrospective data are difficult to understand, so we changed Table 5 as follows.

The odds ratio between the dependent factor (exacerbating factor) and the independent factor has been reduced to 1 or less.

Therefore, we changed "lung disease other than mycobacterial disease, n (%)" to "No lung disease other than MAC disease, n (%)" and corrected each numerical value in Table 5.

As mentioned, when we had consulted with experts about statistics, multivariate analysis with items that are similar was not considered statistically accurate.

Therefore, multivariate analysis was performed using radiological factor (larger affected area), comorbidity (absence of other lung disease), sex (female sex), and smoking (never-smoker), and we created Figure 2 separately.

As regards limitations, we added the following on Page 11,Line 12,

"Limitations Some limitations in our study should be addressed. This study is limited by retrospective nature without randomization, and single-institutional study. In addition, this study has been performed only for those with a definitive diagnosis of MAC disease. Suspected MAC disease, for example, the cases that bacteria were detected by only once with sputum , and the cases that have been treated with MAC diagnosis in the past, have been excluded. So, it is presumed that the number of cases was limited, the number of cases being treated was small, and the elderly were many."

Comment

Reviewer \#1:

The manuscript titled "Predictors of exacerbation of pulmonary MAC disease" is written well and interesting to note the new scoring system for pulmonary involvement. The authors claim that "The new information provided by this study is that the most critical exacerbating factor of pulmonary MAC disease over 1 year is the presence of extensive abnormal shadows, especially the presence of abnormal shadows in ≥3 lobes in the lung. This information had never been reported by previous studies". There is a certain bias in the age group who are all elders above 69. It does not represent the age distribution within a normal population. Besides, there are no representative images to explain the scoring system. The data on the co-relation to sex and smoking status does not add any value to the idea mentioned in the title. Also, only 39 people have received MAC therapy. Although this is a very notable finding by the authors, in my opinion, it does not warrant its publication as a full-length manuscript but a brief communication.

Response

We wish to thank the reviewer for the comments.

This study involved only those with a definitive diagnosis of MAC disease. Suspected cases of MAC disease, for example, the cases in which bacteria were detected only once in sputum and cases treated with a MAC diagnosis in the past, were excluded. Thus, it is presumed that the number of cases was limited, the number of cases being treated was small, and there were many elderly patients.

As you suggested, we added the following on Page11, Lines12, "Limitations Some limitations in our study should be addressed. This study is limited by retrospective nature without randomization, and single-institutional study. In addition, this study has been performed only for those with a definitive diagnosis of MAC disease. Suspected MAC disease, for example, the cases that bacteria were detected by only once with sputum and so on, the cases that have been treated with MAC diagnosis, have been excluded. So, it is presumed that the number of cases was limited, the number of cases being treated was small, and the elderly were many."

As regards our scoring system, our scoring system involves just counting the number of abnormal lesions in the lung fields divided into six zones based on anatomical structures. Thus, we did not show the scoring system.

As mentioned, we deleted Table 5 that was not needed.

However, the number of patients with pulmonary MAC disease is increasing worldwide, especially among women and never-smokers. We did a simple analysis of it, and in the process, we noted that is easier to detect MAC disease relatively early in smokers, because of other diseases. Therefore, we decided to perform an additional analysis.

Comment

Reviewer \#2:

I appreciate your response to my comments. Statistical methods are basically the same. As previously mentioned, there is nothing novel to our clinical practice. The author\'s comment indicates the presence of a scoring system, which is not mentioned in the manuscript.

Response

We wish to thank the reviewer for the comments.

As mentioned, our statistical analysis of the retrospective data was difficult to understand, so we changed Table 5 as follows. The odds ratio between the dependent factor (exacerbating factor) and the independent factor was reduced to 1 or less. Therefore, we changed "lung disease other than mycobacterial disease, n (%)" to "No lung disease other than MAC disease, n (%)" and corrected each numerical value in Table 5.

As mentioned, when we had consulted with experts about statistics, multivariate analysis with the items that are similar was not considered statistically accurate.

Therefore, multivariate analysis was performed using radiological factor (larger affected area), comorbidity (absence of other lung disease), sex (female sex), and smoking (never smoker), and we created Figure 2 separately.

I think, the new information provided by this study is that the most critical exacerbating factor of pulmonary MAC disease over 1 year is the presence of extensive abnormal shadows, especially the presence of abnormal shadows in ≥3 lobes in the lung, and tat female sex and never-smoker were not associated with exacerbations over 1 year.
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Selvakumar Subbian
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, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

25 Mar 2020

PONE-D-19-29751R2

Predictors of exacerbations of pulmonary MAC disease

PLOS ONE

Dear Dr. Matsuse,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR: Unfortunately, this manuscript still lacks the scientific rigor and integrity. There are lots of issues in this manuscript including definition of \"exacerbation\" (refer reviewer\#3 comments), limited number of samples, data interpretation and statistical analysis. As suggested by the reviewers, the authors should consider presenting the data of only treatment-naive patients in the main text. Also, summarize the limitations of this studies and discuss the discrepancy in the findings between this study and previously reported similar studies.

==============================

We would appreciate receiving your revised manuscript by May 09 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Selvakumar Subbian, Ph.D.

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#3: Partly

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

Reviewer \#3: No

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The paper is well written concise about a new scoring system and a pattern for MAC disease. Although interesting the study has limitations of its own and in my opinion does not warrant a publication as full length research article.

This can be an excellent short communication wherever suitable.

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#3: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 2

7 May 2020

PONE-D-19-29751R2

Predictors of radiologic aggravations of pulmonary MAC disease

PLOS ONE

Academic Editor:

We wish to thank the academic editor for the comments.

Comment

There are lots of issues in this manuscript including definition of \"exacerbation\" (refer reviewer\#3 comments), limited number of samples, data interpretation and statistical analysis. As suggested by the reviewers, the authors should consider presenting the data of only treatment-naive patients in the main text. Also, summarize the limitations of this studies and discuss the discrepancy in the findings between this study and previously reported similar studies.

Response

As you suggested, we now present the data only of treatment-naive patients in the main text. We also replaced "exacerbation" with "radiologic aggravation" and added the following on Page 10, Line 19, "In this study, disease progression was defined as aggravation on the radiological image."

As you pointed out, the study period was extended to December 2018 due to the small number of cases, and we also corrected the statistical analysis.

We summarized the limitations of this study and discussed the discrepancy in the findings between this study and previously reported similar studies.

Reviewer

We wish to thank the reviewer for the comments.

Comment

The authors investigated the predictors of exacerbations of pulmonary MAC lung disease. Although the topic addressed in this manuscript is interesting, some of the interpretations underlying the authors\' approach to be flawed. Additional description and further clarification is needed.

Major comments.

1\. The description of the results and the findings of this study were quite confusing. I think this is because the authors used two different definitions with regard to the definition of "exacerbation". That is, "exacerbation" was defined as "the frequency of MAC therapy" in Table 2, Table 3, and Page 10 line 14-16. In contrast, "exacerbation" was defined as "radiologic aggravation" in Figure 2, Table 4, Page 9 line 1-12, and Page 10 line 12-14. Previous studies (Clinical Infectious Diseases 2017;65(6):927--34, Eur Respir J 2017; 49: 1600537, BMJ Open 2015;5:e008058, <http://dx.doi.org/10.5588/ijtld.13.0792>) adopted either, but not both, as a definition of exacerbation.

Response

As suggested, we deleted Table 2 and Table 3, and we present the data only of treatment-naive patients in the main text. We also replaced "exacerbation" with "radiologic aggravation" and added the following on Page 10, Line 19, "In this study, disease progression was defined as aggravation on the radiological image."

Comment

2\. Moreover, in contrast to the authors' description in Page 4 line 17-21, I think there is no previous studies reporting that sex and smoking status were related to the exacerbation (the frequency of MAC therapy) of MAC lung disease. I believe that, if there is any relationship, this may be due to the higher number of fibrocavitary types in men and smokers compared with women and non-smokers. Although radiologic types were not related to the exacerbation in this study, it was likely that the number of enrolled subjects were small to reveal clinical significance. Likewise, there is no reason that sex and smoking status might be related to the radiologic deterioration of MAC lung disease. Therefore, I think that Table2,3, and its relevant descriptions in the Results and Discussion sections are unnecessary because these results had little clinical implications.

Response

As you suggested, there have been no previous studies showing that sex and smoking status were related to the exacerbation (the frequency of MAC therapy) of MAC lung disease.

Therefore, we changed the following on Page 4, Line 21, "In contrast to prevalence, whether sex and smoking status could be factors aggravating pulmonary MAC disease remains unknown."

As you pointed out, the study period was extended to December 2018 due to the small number of cases, and we also corrected the statistical analysis.

Comment

3\. In contrast to previous studies concerning the predictors of radiologic deterioration enrolled both the patients received treatment and treatment-naïve patients (Clinical Infectious Diseases 2017;65(6):927--34, BMJ Open 2015;5:e008058, <http://dx.doi.org/10.5588/ijtld.13.0792>), the authors performed their analysis of predictors of exacerbation using only the data of treatment-naïve patients. I think this is the novel finding of this study. I recommend that the authors focus solely on this part and revise the paper as a whole.

Response

As you suggested, we focused solely on the data of treatment-naïve patients and revised the paper as a whole.

Comment

4\. The term "exacerbation" is confusing. Because "exacerbation" is usually referred to the clinical situation that required treatment. I think "radiologic deterioration" or "radiologic aggravation" should be used instead of "exacerbation" throughout the manuscript.

Response

As you suggested, we replaced "exacerbation" with "radiologic aggravation" throughout the manuscript.

Comment

5\. Page 6, line 6: Reference is needed for this description.

Response

We added a reference.

Comment

6\. The authors should add the data about the number and the percentage of patients with aggravation, no change, and improvement.

Response

As previously mentioned, we deleted Table 2 and Table 3.

Comment

7\. Page 7, line 4-line 6

The analysis of radiographic findings in patients received treatment was not found in the manuscript. However, as I suggested above, I recommend authors to revise the manuscript excluding the patients underwent treatment.

Response

As you suggested, we revised the manuscript excluding the patients who underwent treatment.

Comment

8\. Statistical analysis

1\) For the multivariate logistic analysis, the odds ratio (OR) is used. The hazard ratio is used for the Cox regression analysis.

2\) In addition, higher OR should be associated with an increased risk of radiologic deterioration. However, in Figure 2, lower OR was associated with an increased risk of radiologic deterioration.

Response

As you suggested, we changed "HR" to "OR" and changed it so that higher OR was associated with an increased risk of radiologic aggravation.

Comment

9\. In Table 1, all data are expressed as median value. However, in the Results section, the authors described "average" BMI and "average" number of abnormal lung zone. The mean and median values should be clearly distinguished. Please note that variables with normal distribution should be expressed as mean +/- standard deviation.

Response

In the previous revision, it was pointed out that the mean ± standard deviation should be changed to the median value due to the small number of cases. As suggested, we clearly distinguished the mean and median values.

Comment

10\. Author might want to add new Table according to the radiologic aggravation, instead of Table 4.

Response

As suggested, we changed "exacerbation" to "radiologic aggravation."

Comment

11\. In Table 4, "no" lung disease other than MAC disease was a statistically significant predictor in univariate analysis. However, in the Result and Discussion section, it was described that "fewer" lung disease other than MAC was a significant factor. I think that "no" and "fewer" was totally different.

Response

As suggested, we corrected it to "no lung disease other than MAC".

Comment

12\. In Table 4, it seems that "zone of radiologic findings", involved lobes ≥2, and involved lobes ≥3 were variables that were highly correlated with one another. In the multivariate logistic analysis, if two or more variables are highly correlated with one another, it is hard to get good estimates of their distinct effects on some dependent variable. The authors should check multicollinearity in their statistical analysis.

Response

As you suggested, if two or more variables are highly correlated with one another, it is hard to obtain good estimates of their distinct effects on a dependent variable.

Therefore, regarding the number of abnormal lesions, the sensitivity and specificity of the radiologic aggravation prediction model were calculated for each score value. We added Figure 3 and Figure 4. The performance of the radiologic aggravation prediction model was evaluated using the receiver operating characteristic (ROC) curve with the calculation of the area under the ROC curve.

Comment

13\. Page 10, line 4-line 5

Such results cannot be found in the manuscript.

Response

We deleted the sentence.

Minor comments.

1\. Page 4, line 10-line 11: The authors might want to use "guideline-based therapy" instead of "standard therapy".

Response

As you suggested, we used "guideline-based therapy" instead of "standard therapy".

Comment

2\. Page 6, line 19: clinical course � radiologic image?

Response

We changed "clinical course" to "radiologic image".

Comment

3\. Page 8, line 1: M. avium -- 100/128 (78.1%), M. intracellulare -- 21/128 (16.4%), mixed infection -- 7/128 (5.5%)

Response

We corrected it.

Comment

4\. Page 8, line 5: BMI 19.1 -- However, BMI was 19.0 in Table 1

Response

We corrected it.

Comment

5\. Tables: positive MAC smear � positive AFB smear

Response

We replaced "positive MAC smear" with "positive AFB smear," as suggested.

Comment

6\. Page 10, line 18, Page 11, line 1: treatment "resistance" is an inappropriate word.

Response

We deleted the term.
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29 May 2020

PONE-D-19-29751R3

Predictors of radiologic aggravations of pulmonary MAC disease

PLOS ONE

Dear Dr. Matsuse,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.
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ACADEMIC EDITOR: The authors should pay serious attention in reviewing their manuscript for uniformity, language and order to improve the quality. Take into consideration all the reviewer comments and address them at the appropriate place in the manuscript.
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Please submit your revised manuscript by Jul 13 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:
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Selvakumar Subbian, Ph.D.

Academic Editor
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#3: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The manuscript "Predictors of radiologic aggravations of pulmonary MAC disease" is a neat and simple analysis. However, discussion of the results obtained should be more precise and clearer to benefit the readers. Grammar and language can be redone more rigourously. Overall formatting needs to be uniform. References can be more updated ones

Revisions:

Page 4

Line 3 : Please update the references. The quoted ones are more than a decade old.

Page 8

Lines 13-17 can be simplified for easy understanding

Line 18 "Multivariate analysis was performed with items that showed significant differences on univariate analysis". Please change the word "items" to a more scientific word.

Line 23 Please elaborate "additional analysis"

Page 9

Line 16 -18 "A recent biological study reported the role of oestrogen in the development of pulmonary MAC disease, whereas the role of sex in disease susceptibility has yet to be determined"

The quoted reference dates back to 2001. Please use an update reference or avoid the word recent.

Line 18-19 "Generally, pulmonary MAC diseases develop more frequently in thin patients". Please provide appropriate reference.

Line 20 -- Nutritional status was suggested by whom. Please be more scientific in discussion.

Line 22 -- "Adiponectin might be involved". This could be elaborated.

Page 10, 11 When you discuss the association of positive smear as an aggravating factorm it needs to be more precise and clearer. It is better to rewrite the univariate and multivariate analysis results more clearly.

Table 2: Please change the "See footnotes of Tables 1 and 2 for expansions of abbreviations " to table 1 and not as table 1 and 2. Mention interquartile ranges and significant \* p value for benefit of readers.

Figure 3: please clearly define the Y axis and explain the same in legend

Figure 4: Please explain the plot and mention the cutoff rather than just giving the title

Reviewer \#3: The authors have responded well to my suggestions and revised the paper superbly. However, some major corrections and further clarification are still strongly needed.

Major comments.

1\. Page 4, line 17-22

After major revision, the authors have revised their manuscript by deleting the findings and its relevant descriptions concerning the sex and smoking status (such as Table 2 and Table 3 in the previous manuscript). Therefore, I think that these sentences should be deleted (or at least modified) in the revised manuscript. Instead, authors should add the descriptions about the "radiologic aggravation", such as the results of the previous studies and unknown findings so far.

2\. Page 3, line 10

Keywords should be modified. Namely, "sex" and "smoking status" should be removed from the keywords. Instead, authors might want to add the other keywords related to the radiological aggravation.

3\. Page 8, line 1, Page 8, line 7, Figure 1, Table 2

238 (the number of total patients with MAC lung disease) -- 62 (the number of patients received treatment) = 176

However, in Figure 1 and Table 2, the number of treatment-naïve patients was 167. Please clarify this.

4\. Discussion

1\) The sentence and paragraph of Discussion section is too fragmentary (In particular, Page 10, line 5-line 14, Page 11, line 21-line 23). Authors should rewrite Discussion section in a more comprehensive way.

2\) In addition, I think that many descriptions in the Discussion section are generally irrelevant (In particular, Page 9 line 11-page 10 line 4, Page 10 line 12-line 14) to the main findings of the present study.

3\) Page 10, line 19-Page 11, line 4: These sentences are simple repetitions of those described in the Result section.

4\) Page 11, line 4 "female sex, never-smoker": In the revised manuscript, I think that there is no more reason to make an assumption that gender or smoking status are related to radiologic aggravation.

5\) Page 11, line 9: these studies -\> previous studies

6\) Page 11, line 9-line 11: Please add reference for this sentence.

7\) Page 11, line 12: the presence -\> the presence or absence

8\) Page 11, line 19-line 20: Please delete this sentence.

9\) Page 12, line 2: limitations -\> I think that the Authors' scoring system has "merit" over the previous scoring system, rather than "limitation".

10\) Page 12, line 16-19: I do not believe that this is the limitation of the present study. Because the aim of the present study is to investigate the predictors of radiologic aggravation in "treatment-naïve" patients diagnosed with MAC lung disease "according to the ATS criteria".

11\) Page 12, line 19-20 "the number of cases being treated was small": Authors have already excluded the patients who received treatment. Therefore, these patients were not included in the main analysis of the present study.

12\) Page 12, line 24 "the most critical factor": As figure 2 shows, "no lung disease other than MAC" has higher OR than radiologic involvement. Therefore, I do not understand why "more extensive radiological findings" was the "most" critical factor of radiologic aggravation.

Minor comments.

1\. Page 2, line 14-15: the natural predictors of exacerbation -\> the predictors of radiologic aggravation

2\. Page 2, line 18: were common -\> were predominant

3\. Page 5, line 13: also -\> please delete

4\. Page 7, line 3-line 6 -\> please consider to delete this sentence

5\. Page 8, line 16-17, "whereas female sex \~ aggravations" -\> please delete this sentence.

6\. Table 1, smoking history: 2+76+154+10 = 242, not 238

7\. Table 1, previous tuberculosis: 23/238 = 9.7%, not 8.8%

8\. Table 2: see footnotes of Table 1 and Table 2 -\> see footnote of Table 1

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#3: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Academic Editor:

We wish to thank the academic editor for the comments.

Our previous study period was extended to December 2018 due to the small number of cases; thus, we changed the project registration number with the ethics committee from H16053 to H20004.

Reviewer \#1: The manuscript "Predictors of radiologic aggravations of pulmonary MAC disease" is a neat and simple analysis. However, discussion of the results obtained should be more precise and clearer to benefit the readers. Grammar and language can be redone more rigourously. Overall formatting needs to be uniform. References can be more updated ones

We wish to thank the reviewer for the comments.

Comment

Page 4

Line 3 : Please update the references. The quoted ones are more than a decade old.

Response

We updated the references (\#1-\#5).

Comment

Page 8

Lines 13-17 can be simplified for easy understanding

Response

We changed the following sentences.

"The results indicated that no lung diseases other than MAC, more extensive radiological findings, and positive AFB smear were significantly associated with radiologic aggravations, whereas female sex and never-smoker were not found to be significantly associated with radiologic aggravations."

→"The univariate analysis showed that no lung diseases other than MAC, more extensive radiological findings, and positive AFB smear were significantly associated with radiological aggravations."

Comment

Line 18 "Multivariate analysis was performed with items that showed significant differences on univariate analysis". Please change the word "items" to a more scientific word.

Response

As you mentioned, we replaced "items" with "factors".

Comment

Line 23 Please elaborate "additional analysis"

Response

We added " ROC curve analysis" after additional analysis.

Comment

Page 9

Line 16 -18 "A recent biological study reported the role of oestrogen in the development of pulmonary MAC disease, whereas the role of sex in disease susceptibility has yet to be determined"

The quoted reference dates back to 2001. Please use an update reference or avoid the word recent.

Response

As you suggested, we updated the references (\#22).

Comment

Line 18-19 "Generally, pulmonary MAC diseases develop more frequently in thin patients". Please provide appropriate reference.

Response

We added the references (\#23-25 ).

Comment

Line 20 -- Nutritional status was suggested by whom. Please be more scientific in discussion.

Response

It was also pointed out that the nutritional status and so on, as an onset factor, has little relationship to the main findings of present study. Thus, we deleted the sentence about the onset factor appropriately.

Comment

Line 22 -- "Adiponectin might be involved". This could be elaborated.

Response

We think this is true, but, as described previously, we deleted the sentence about the onset factor.

Comment

Page 10, 11 When you discuss the association of positive smear as an aggravating factorm it needs to be more precise and clearer. It is better to rewrite the univariate and multivariate analysis results more clearly.

Response

To make the univariate and multivariate analysis results easier to understand, we added

the following on Page 8, Lines 16-17, "(no lung diseases other than MAC, more extensive radiological findings, and positive AFB smear)"

Comment

Table 2: Please change the "See footnotes of Tables 1 and 2 for expansions of abbreviations " to table 1 and not as table 1 and 2. Mention interquartile ranges and significant \* p value for benefit of readers.

Response

We replaced "Table 1 and Table 2" with "Table 1".

We added interquartile ranges and significant \* p values.

Comment

Figure 3: please clearly define the Y axis and explain the same in legend

Response

We clearly defined the Y axis and provided an explanation in the legend.

Comment

Figure 4: Please explain the plot and mention the cutoff rather than just giving the title

Response

We added "zones of abnormal findings, AUC= 0.765"in Figure 4 and the cutoff value in the Figure legend.

Reviewer \#3: The authors have responded well to my suggestions and revised the paper superbly. However, some major corrections and further clarification are still strongly needed.

We wish to thank the reviewer for the comments.

Major comments.

Comment

Page 4, line 17-22

After major revision, the authors have revised their manuscript by deleting the findings and its relevant descriptions concerning the sex and smoking status (such as Table 2 and Table 3 in the previous manuscript). Therefore, I think that these sentences should be deleted (or at least modified) in the revised manuscript. Instead, authors should add the descriptions about the "radiologic aggravation", such as the results of the previous studies and unknown findings so far.

Response

As you mentioned, we deleted the descriptions concerning sex and smoking status and changed to the following on Page 4, Lines 16-23, "Other factors that are currently considered to aggravate pulmonary MAC disease are the presence of fibrocavitary type on radiography, a positive acid-fast bacilli (AFB) smear of sputum samples, and a larger affected area.7,14,16-18 However, there have been few studies of the factors that exacerbate pulmonary MAC disease without treatment, and they were generally judged based on the initiation of treatment as an indicator of aggravation. Thus, the aim of the present study was to clarify the significant predictors of radiological aggravations of pulmonary MAC disease using only the data of treatment-naïve patients."

Comment

2\. Page 3, line 10

Keywords should be modified. Namely, "sex" and "smoking status" should be removed from the keywords. Instead, authors might want to add the other keywords related to the radiological aggravation.

Response

We added "radiological aggravation" instead of "sex" and "smoking status" as a keyword.

Comment

3\. Page 8, line 1, Page 8, line 7, Figure 1, Table 2

238 (the number of total patients with MAC lung disease) -- 62 (the number of patients received treatment) = 176

However, in Figure 1 and Table 2, the number of treatment-naïve patients was 167. Please clarify this.

Response

We excluded 9 patients who could not be evaluated by chest CT one year after MAC diagnosis. Thus, we added the following on Page 5, Line 13 and the exclusion criteria of Figure 1 "radiographic findings were evaluated at the time of diagnosis and 1 year later."

Comment

4\. Discussion

1\) The sentence and paragraph of Discussion section is too fragmentary (In particular, Page 10, line 5-line 14, Page 11, line 21-line 23). Authors should rewrite Discussion section in a more comprehensive way.

Response

As you mentioned, we changed the sentences, and rewrote the following on Page 9, line 19-Page 10, line 13, "The aim of the present study was to clarify the significant predictors of radiological aggravations of pulmonary MAC disease using only the data of treatment-naïve patients. To date, disease progression of pulmonary MAC disease was defined as either requiring the start of treatment7,14,17 or the presence of aggravation on radiological imaging26,27. In the present study, disease progression was defined as aggravation on radiological imaging. In some previous studies, the reason that the initiation of treatment was defined as an indicator of exacerbation was that MAC is indolent in nature, and thus, in many cases, radiological changes are difficult to evaluate on chest X-ray, detailed evaluation requires chest CT, and no radiological evaluation method for pulmonary MAC disease has been established globally. However, the timing of treatment may be biased by each doctor and each patient when using the initiation of treatment as evidence of exacerbation. For example, elderly patients tend to disagree with long-term medication, even if the doctor suspects deterioration and considers that they should be treated. Fortunately, in most of the present cases, CT was performed in our hospital, and it was possible to examine the changes in radiological evaluations. In the present study, radiological aggravation over one year was found in 56/167 (33.5%) of treatment-naïve subjects. Previous studies reported that about 20-40% and 50% of pulmonary MAC patients showed radiological aggravations after 5 and 10 years, respectively.16,26. In the present study, the frequency of radiological aggravations was relatively high within only one year because of the absence of treatment."

Comment

2\) In addition, I think that many descriptions in the Discussion section are generally irrelevant (In particular, Page 9 line 11-page 10 line 4, Page 10 line 12-line 14) to the main findings of the present study.

Response

As you mentioned, we think that page 9 line 11-page 10 line 4 is irrelevant to the main findings of the present study. We deleted page 10 lines 12-14, as mentioned. However, this is a summary statistic of MAC pulmonary disease, and in order to prove that there is no significant difference from the general pulmonary MAC disease reports, it has been shortened significantly.

Comment

3\) Page 10, line 19-Page 11, line 4: These sentences are simple repetitions of those described in the Result section.

Response

As you mentioned, we deleted these sentences and changed to the following on Page 10, Line 19-Page 11, line12, "Previous studies reported that, in addition to extensive radiological findings, positive sputum AFB7,17 smear, FC type7,16, and lower BMI16,18 were aggravating factors. It is difficult to make a strict comparison between the current study and previous studies, because previous studies that treated patients are included, or they defined exacerbation as requiring treatment. In the present study, positive AFB smear, FC type, and lower BMI were not associated with radiological aggravations, but positive AFB smear (OR 3.020, 1.358-6.715) tended to be more common in patients with MAC disease aggravations.No studies examined the presence or absence of underlying lung diseases as an aggravating factor in pulmonary MAC disease. The present study demonstrated that the absence of other underlying lung diseases in untreated MAC patients was a significant aggravating factor of pulmonary MAC disease. Patients having other underlying lung diseases seemed to undergo radiological examinations more frequently than those without other underlying lung diseases. Thus, there may be more opportunities to identify the early phase of pulmonary MAC disease in those with underlying lung diseases. However, it cannot be ruled out that the diseases themselves, such as some kind of lung disease, and part of their treatment may be factors that suppress the progression of pulmonary MAC disease.28 These will be our future research targets."

Comment

4\) Page 11, line 4 "female sex, never-smoker": In the revised manuscript, I think that there is no more reason to make an assumption that gender or smoking status are related to radiologic aggravation.

Response

Based on your comment, we deleted these sentences.

Comment

5\) Page 11, line 9: these studies -\> previous studies

Response

We replaced "these studies" with "previous studies", as suggested.

Comment

6\) Page 11, line 9-line 11: Please add reference for this sentence.

Response

We added a reference.

Comment

7\) Page 11, line 12: the presence -\> the presence or absence

Response

We replaced "the presence" with "the presence or absence", as suggested.

Comment

8\) Page 11, line 19-line 20: Please delete this sentence.

Response

We deleted this sentence, as suggested.

Comment

9\) Page 12, line 2: limitations -\> I think that the Authors' scoring system has "merit" over the previous scoring system, rather than "limitation".

Response

As you mentioned, we replaced "several limitations" with "some limitations and merits."

Comment

10\) Page 12, line 16-19: I do not believe that this is the limitation of the present study. Because the aim of the present study is to investigate the predictors of radiologic aggravation in "treatment-naïve" patients diagnosed with MAC lung disease "according to the ATS criteria".

Response

Thank you for your comment. As suggested, we changed the limitations. "Some limitations of the present study should be addressed. This study was limited by its retrospective nature without randomization, and it was a single-institution study, and as such, it is not representative of the national population.Additionally, this was a short-term study, and the number of MAC patients may have been underestimated since patients who were not diagnosed according to the 2007 American Thoracic Society/Infectious Disease Society guideline were excluded from the analyses. Therefore, factors with clinical significance in reality may have proven insignificant in the analyses with reduced statistical power."

Comment

11\) Page 12, line 19-20 "the number of cases being treated was small": Authors have already excluded the patients who received treatment. Therefore, these patients were not included in the main analysis of the present study.

Response

We deleted the sentences, and made the changes mentioned above.

Comment

12\) Page 12, line 24 "the most critical factor": As figure 2 shows, "no lung disease other than MAC" has higher OR than radiologic involvement. Therefore, I do not understand why "more extensive radiological findings" was the "most" critical factor of radiologic aggravation.

Response

Based on this comment, we deleted "most".

Comment

Minor comments.

1\. Page 2, line 14-15: the natural predictors of exacerbation -\> the predictors of radiologic aggravation

Response

We corrected it as suggested.

Comment

2\. Page 2, line 18: were common -\> were predominant

Response

We changed it as suggested.

Comment

3\. Page 5, line 13: also -\> please delete

Response

We deleted it as suggested.

Comment

4\. Page 7, line 3-line 6 -\> please consider to delete this sentence

Response

We deleted this sentence as suggested.

Comment

5\. Page 8, line 16-17, "whereas female sex \~ aggravations" -\> please delete this sentence.

Response

We deleted this sentence as suggested.

Comment

6\. Table 1, smoking history: 2+76+154+10 = 242, not 238

Response

We corrected it.

Comment

7\. Table 1, previous tuberculosis: 23/238 = 9.7%, not 8.8%

Response

We corrected it.

Comment

8\. Table 2: see footnotes of Table 1 and Table 2 -\> see footnote of Table 1

Response

We corrected it.
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Dear Dr. Matsuse,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Selvakumar Subbian, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No
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If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.
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